Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04225936 · ClinicalTrials.gov registry record · Phase 1
A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04225936 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 40 participants.
The verdict
NCT04225936, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the effect of liver impairment on the safety and pharmacokinetics (PK) of BMS-986263
Interventions
- DRUG BMS-986263
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2021-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04225936
The ClinicalTrials.gov registry entry for NCT04225936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986263 is the first listed.
NCT04225936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04225936 about?
NCT04225936 is a clinical study titled "A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment". The primary purpose of this study is to evaluate the effect of liver impairment on the safety and pharmacokinetics (PK) of BMS-986263
What is the current status of trial NCT04225936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-01-16. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT04225936?
The interventions under investigation include: BMS-986263 (DRUG).
Who is sponsoring clinical trial NCT04225936?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.